Tuesday, August 01, 2017

Steroid Tapering Design Clinical Trials

In the most recent issue of New England Journal of Medicine, Stone et al published the results from "Trial of Tocilizumab in Giant-Cell Arteritis". The study used a steroid tapering design with the primary efficacy endpoint of "the rate of sustained glucocorticoid-free remission at week 52 in each tocilizumab group as compared with the rate in the placebo group that underwent the 26-week prednisone taper."

There are some chronic diseases where the effective treatment is the high dose of steroid (corticosteroid, prednisone,...). To control the symptoms, the patients are usually put on the long-term use of the high dose steroid. While the steroid treatment may be effective, it can cause serious, irreversible side effects.

The list of side effects of long-term steroid use includes, but not limited to:
  • mood changes 
  • forgetfulness 
  • hair loss 
  • easy bruising 
  • a tendency toward high blood pressure and diabetes 
  • thinning of the bones (osteoporosis)
  • suppression of the adrenal glands
  • muscle weakness
  • weight gain
  • cataracts 
  • glaucoma

It will be useful to develop an alternative treatment that can replace the long-term steroid use or at least minimize the steroid dose required. To investigate the effect of the alternative treatment, clinical trial can be designed to demonstrate if the alternative treatment can taper down the steroid dose to very low or zero level while maintaining the stabilized symptoms – we call this as steroid tapering or steroid sparing design.

In a steroid tapering design, the purpose of the study is not to pursue the further improvement in disease symptoms. The steroid tapering design will have a study endpoint based on the reduction in the steroid dose while maintaining the stabilized symptoms. The possible efficacy endpoints could be the following:
  • Steroid dose reduction at Week xx from baseline
  • Percent of subjects with zero steroid dose at Week xx
  • Percent of subjects with steroid dose less than xx mg at Week xx
  • Percent of subjects with steroid dose reduction greater than and equal to 50%
  • AUC for steroid dose between week x to week y

In one of studies investigating the steroid tapering effect of IGIV in generalized myasthenia gravis, FDA confirmed during the pre-IND meeting that the treatment effect in reducing the steroid dose is meaningful.  This study is sponsored by Grifols and is currently ongoing. as indicated in clinicaltrials.gov, the sponsor chose "the percent of subjects with steroid dose reduction greater than and equal to 50%" as the primary efficacy endpoint. 
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
When designing a steroid tapering trial, the following issues need to be addressed:
  • Steroid tapering design has a wash-in, wash-out feature. With the effect of new treatment kicking in (if the active treatment is effective), the dose of the steroids will be reduced.
  • The purpose of the study is not the improvement in disease symptoms. The purpose is to maintain the symptoms (no deterioration) while the steroid dose is reduced. 
  • Considering the withdrawal effect of the steroid, steroid tapering design will therefore include a run-in period – the early period when the new treatment added, but steroid tapering has not started yet. To ensure the patient safety, the steroid dose tapering will only start at the end of the run-in period. During the run-in period,
  • Changes / reductions in steroid dose could influence outcomes; The treatment effect of steroid reduction must be established on the maintenance of the disease symptoms. There should be a rule to define the worsening of the clinical symptoms when the tapering must be slowed or stopped. There must be a standardized steroid tapering regimen and standardized rescue measure when disease symptoms exacerbated due to the steroid tapering.
  • Subjects who entered into the study and before the randomization should have a stable steroid dose. If the patients are not on stable steroid dose while entering the study, at the end of the study, it is not possible to tease out if the steroid dose reduction is due to the fluctuation of the steroid dose itself or due to the effect of the new treatment.
  • The stratified randomized can be used to include the baseline steroid dose category as a stratification factor to ensure that within each steroid dose category, equal number of subjects are randomized into active treatment or placebo control. Patients on higher steroid dose at baseline are more likely to have steroid dose reduction. The stratified randomization can minimize the biases due to this.
  • If the endpoint is “the mean change from baseline in steroid dose”, the magnitude of the steroid reduction between two treatment group needs to be clinically meaningful.
  • In steroid tapering design, there must be a rescue plan in the case of symptom worsening / deterioration (or exacerbation) due to the decrease in steroid dose.  
  • At the end of the study, there should be a safety follow-up period. 

There is a FDA Guidance for Industry Systemic Lupus Erythematosus — Developing Medical Products for Treatment where the steroid tapering design is proposed. 
d. Reduction in concomitant steroids Reducing corticosteroid use is an important goal in treatment of patients with SLE if it occurs in the context of a treatment that effectively controls disease activity. Therefore, for a medical product to be labeled as reducing corticosteroid usage, it should also demonstrate another clinical benefit, such as reduction in disease activity as the primary endpoint. In an add-on trial to test the steroid-sparing potential of a new medical product, patients should be enrolled during a flare and randomized to the addition of the new medical product or placebo to induction doses of corticosteroids. In both study arms, when patients achieve quiescent disease, the corticosteroid dose should be tapered to a maintenance dose that is not usually associated with major toxicities while still maintaining quiescence. The induction steroid dosage and duration of induction therapy and taper schedule should be based on the severity of disease activity in the dominant organ system involved.8 The evaluation of efficacy should be based on the proportion of patients in treatment and control groups that achieve a reduction in steroid dose to less than or equal to 10 mg per day of prednisone or equivalent, with quiescent disease and no flares (see definition above) for at least 3 consecutive months during a 1-year clinical trial. For a result to be clinically meaningful, the patient population should be on moderate to high doses of steroids at baseline. Trials should also assess the occurrence of clinically significant steroid toxicities.

The steroid tapering design can be used in various disease areas, the following examples are the application of steroid tapering design in severe refractory asthma, myasthenia gravis, systemic lupus erythmatosus, giant cell arteritis (GCA), and severe asthma. 

The primary measure of efficacy in our study will be the nine-month prednisone AUC (months 3–12), which measures the total prednisone doses of each patient in nine months. A reduction of prednisone AUC demonstrates that patients improved on clinical grounds so that the prednisone dose could be decreased. If the patients receiving MTX have a smaller prednisone AUC compared to the placebo patients, this will have demonstrated the efficacy of MTX. 
Based on pre-IND discussions with FDA and consultants, it was decided that the primary efficacy variable for the corticosteroid reduction study should be, for patients who were corticosteroid dependent, a reduction of the patients’ current prednisone dose to 7.5 mg/day (upper limit of physiologic levels) or less, without worsening of SLE.
The design of the steroid sparing study was a forced titration; i.e., the patient’s steroid dose at each monthly visit was to be reduced, by algorithm, if her disease activity was stable or improved. However, when a patient worsened or flared, the associated increase in corticosteroid dose, if any, required to treat the patient’s exacerbation was at the physician’s discretion and not by algorithm. The steroid reduction algorithm was based on the patient’s disease activity improving or being stable, which was defined as no change in or a decrease in SLEDAI score in comparison to her previous visit. As such, one of the issues discussed at the pre-study investigator meeting was whether patients with low SLEDAI scores, and especially those with SLEDAI scores of 0, should be enrolled into the study. There was concern that those patients with low SLEDAI scores had inactive disease, and therefore would not be affected by steroid reduction, i.e., might not be steroid dependent. However, some investigators and consultants felt that if patients were truly dependent on steroids, their low SLEDAI scores represented active disease suppressed by corticosteroids, which would worsen or flare as soon as their corticosteroids were reduced. Therefore, because there was no experience with such trials, it was decided not to exclude patients with low SLEDAI scores. The concern regarding enrollment of potentially inactive SLE patients was revisited prior to unblinding of the study. In addition it was recognized that because of the forced downward titration of steroid dose as the patients’ disease improved or remained stable, other evaluations of disease activity such as SLEDAI, etc., would not be expected to improve.
The pivotal study was designed as a double-blind, randomized, placebo-controlled, parallel group trial to evaluate GL701 100 and 200 mg/day versus placebo in female patients with mild to moderate prednisone-dependent systemic lupus erythematosus (SLE).
The study included two primary efficacy variables. The first one was responder rate. A responder was defined as a patient with the achievement of a decrease in prednisone dose to 7.5 mg/day or less sustained for no less than three consecutive scheduled visits, including the termination visit (i.e., two consecutive months), on or after Visit 7. The second primary efficacy variable was percent decrease in prednisone dose determined by comparing the prescribed prednisone (or steroid equivalent) dose at Baseline (Qualifying Visit) and the last visit prednisone dose using the physician prescribed prednisone dose recorded on the Medication Record Form.
  • Elimumab May Have Potential As A Corticosteroid-Sparing Drug When Added To Standard-Of-Care Treatment For SLE, Research Suggests.
Research suggests “the monoclonal antibody belimumab (Benlysta) may have potential as a corticosteroid-sparing drug when added to standard-of-care treatment for systemic lupus erythematosus (SLE).” Investigators found, “in pooled data from two large randomized controlled trials,” that “this blocker of B-lymphocyte stimulator was moderately associated with a higher probability of corticosteroid dose reduction and a greater average dose reduction over” one year. The findings were published in Arthritis & Rheumatology.
This paper described the design and operationalization of a blinded corticosteroid-tapering regimen for a randomized trial of tocilizumab in giant cell arteritis (GCA). The study design is sketched in the diagram below. The primary efficacy endpoint is “Proportion of patients in sustained remission at week 52 following induction and adherence to the protocol-defined prednisone taper regimen”


6 comments:

Cloud said...

hi!

SteroidSp said...



As the use of Steroid increases day by day, the need for sources of information on steroids is rapidly increasing. In this respect, our site aims to inform the athletes about steroid use as best we can, as they are well aware of the problems that may arise after the unconscious use of steroids. While those who log in to my site can easily review the product they want on my site, they also display the best cursors they can get according to their needs. On this side, it is very similar to the sports, as well as the cure and research and the use of steroids. After this process, development process can be followed easily.

Our site offers a safe shopping opportunity from the time it was set up to serving people who are considering buying steroids. Our company, which sells all products recommended in the steroid industry, constantly offers the best prices on the easiest conditions at this stage. It is enough for the customers who can buy steroids by credit card or bank transfer method to decide which product they are going to use. In addition, discounted prices will be offered to our customers who will receive products in a wholesale manner, so that all opportunities will be provided to the athletes. If there are people completing their shopping on our site until 14:30 noon, the products they receive are delivered to the cargo on the same day. This means that the products will be delivered on the next day or second day, even if they depend on the city.

While all of our products are offered in categorized form on our site, after selecting products from these categories, people will be able to use credit cards together with private security systems. When credit cards are used, the information to be given is definitely not seen by any person, but they are directly directed to the bank's page to make purchases. In this way, customers will be able to reply to our site easily while they are in contact with our phone numbers and e-mail addresses. Thus, the problems that arise will be immediately solved in favor of our customers and the best contribution to our customers' sports will be given.

Victor House said...

Over the years, it has been used to treat diseases that cause muscle wastage such as cancer. It is also used to treat Bell's palsy during the initial stages. Old people suffer from Alzheimer's due to low testosterone levels and it is ideal to note that these can also be used to treat the same.

steroid like supplements

Sarah Evans said...

Steroids might affect some medical conditions, such as diabetes, heart or blood pressure problems, or mental health issues. If you have any of these conditions, the person treating you will need to make sure the steroids aren’t making the condition worse. Visit: buy steroid Canada

Peter said...

Very nice content and I have learned much from this blog about real steroids.

SEO said...

Nice http://onbiostatistics.blogspot.com/2017/07/steroid-tapering-design-clinical-trials.html